Nanotechnology for viral diseases

Numerous zoonotic and non-zoonotic viruses possess the potential to spark pandemics. A zoonotic virus denotes a virus transmitted from an animal to a human, often involving a secondary human intermediary. SARS-CoV-2, for instance, is hypothesized to have originated from bats, possibly via an as-yet-unidentified secondary host. A critical observation regarding traditional antiviral medications is their inadequacy in combatting most viruses, particularly emerging zoonotic variants, which lack effective drugs or vaccines against the spectrum of virus-induced ailments.
Various concerns have surfaced regarding current antiviral treatments and vaccines. Notably, the research and production costs of vaccines are not deemed economically viable. A study featured in the Pharmaceutics journal underscores the robust potential of flavonoids in combatting viral diseases. It suggests that employing diverse nanodelivery systems and nanoformulations could significantly enhance the delivery of lipophilic flavonoids. This, in turn, could facilitate targeted drug administration and enhance the bioavailability of flavonoid compounds. The refinement of this entire process could potentially revolutionize prevailing notions concerning antiviral medications and their delivery modalities.